Jardiance is one of the most commonly prescribed SGLT2 inhibitors for type 2 diabetes, heart health, and kidney-related conditions. However, several alternatives are available, including Farxiga, Invokana, and Steglatro. While these medications work similarly, differences in pricing, insurance coverage, side effects, and online availability may influence which option is most suitable for different patients.
Patients comparing medication access and pricing can also review our Jardiance vs Farxiga pharmacy comparison for provider availability and online pharmacy comparisons.
How Jardiance Compares With Other SGLT2 Inhibitors
Jardiance belongs to a class of medications known as SGLT2 inhibitors, which are commonly prescribed for type 2 diabetes and may also support heart and kidney health. Other medications in this category include Farxiga, Invokana, and Steglatro.
Although these medications work in similar ways, important differences exist in insurance coverage, pricing, approved uses, and provider availability. Some medications may also be more widely available through online pharmacies than others.
Common SGLT2 Inhibitor Options
- Jardiance (empagliflozin) – Commonly prescribed for diabetes, heart health, and kidney-related conditions.
- Farxiga (dapagliflozin) – Frequently used for diabetes and heart failure management.
- Invokana (canagliflozin) – One of the earlier SGLT2 medications approved in the United States.
- Steglatro (ertugliflozin) – A newer SGLT2 inhibitor with more limited availability.
If you’re evaluating broader treatment categories, our guide to GLP-1 vs SGLT2 inhibitors compares these medication classes for weight loss, diabetes treatment, and medication access.
Effectiveness for Diabetes and Weight Loss
All SGLT2 inhibitors, including Jardiance and its alternatives, effectively lower blood glucose and promote modest weight loss, making them valuable tools in diabetes management and weight loss diabetes medication strategies.
Blood Glucose Control: Clinical trials consistently demonstrate that SGLT2 inhibitors reduce HbA1c levels by 0.5-1.5%, depending on baseline glucose control and dosing. Jardiance typically reduces HbA1c by 0.7-0.8% in monotherapy, which is comparable to other SGLT2 inhibitors. This glucose-lowering effect is achieved without increasing the risk of hypoglycemia, a significant advantage over insulin secretagogues and insulin itself.
Weight Loss Benefits: One of the most appealing benefits of SGLT2 inhibitors is their weight loss effect. Because glucose is excreted in urine, patients essentially lose calories through glucose elimination. Clinical trials show that SGLT2 inhibitor therapy results in an average weight loss of 2-3 kg, with some patients experiencing greater loss. This weight reduction occurs through caloric loss rather than appetite suppression, making it a unique mechanism among diabetes medications. For patients struggling with obesity-related type 2 diabetes, this benefit can be particularly valuable.
Additional Metabolic Benefits: Beyond glucose and weight control, SGLT2 inhibitors improve multiple cardiometabolic parameters. These medications reduce blood pressure by 3-5 mmHg, lower triglycerides, and improve cholesterol profiles. The metabolic benefits extend to reduced uric acid levels, an added advantage for patients with gout history. These comprehensive metabolic improvements make type 2 diabetes medications like Jardiance valuable for comprehensive cardiovascular risk reduction.
Side Effects and Safety Considerations
SGLT2 inhibitors are generally well tolerated, but they may increase the risk of dehydration, urinary tract infections, and yeast infections in some patients. Individual side effects and risks can vary depending on the medication and the patient’s overall health profile.
Patients should always discuss treatment options, side effects, and medication suitability with a licensed healthcare professional before starting a new prescription medication.
Cost and Insurance Coverage
The cost of Jardiance and other SGLT2 inhibitors can vary depending on insurance coverage, pharmacy pricing, manufacturer savings programs, and whether the medication is purchased locally or through online pharmacies.
Patients specifically researching Farxiga pricing and insurance options can also read our guide to Farxiga cost, insurance coverage, and savings options.
Many insurance plans now cover SGLT2 inhibitors for approved uses, although copays and coverage restrictions may differ significantly between providers and medications.
Conclusion
Jardiance and other SGLT2 inhibitors offer several potential benefits for patients managing type 2 diabetes and related conditions. While these medications share similarities, differences in pricing, insurance coverage, side effects, and online availability may influence which option is most appropriate.
Patients comparing providers and prescription access can also visit our online pharmacy comparison guide for additional medication and pharmacy comparisons.
Reviewed by: Dr Mattias Hagman, PhD
About the reviewer: Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last updated: May 2026
Sources and Further Reading
This article is for informational purposes only and does not provide medical advice. Always consult a licensed healthcare professional regarding prescription medications and treatment decisions.